Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Trading 08-10 11:20:36 EDT

27.45

+0.10

+0.35%

High28.09	Low27.07	Vol143.01K
Open27.09	D1 Closing27.35	Amplitude3.73%
Mkt Cap2.42B	Tradable Cap1.81B	Total Shares88.16M
T/O3.93M	T/O Rate0.22%	Tradable Shares66.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":27.445,"timestamp":1786375222767,"preClose":27.35,"halted":0,"volume":143013,"delay":0,"changeRate":0.003473491773308916,"floatShares":66025800,"shares":88158500,"eps":-2.021721,"marketStatus":"Trading","change":0.095,"latestTime":"08-10 11:20:36 EDT","open":27.09,"high":28.09,"low":27.07,"amount":3925094.75436,"amplitude":0.037294,"askPrice":27.46,"askSize":212,"bidPrice":27.41,"bidSize":40,"shortable":3,"etf":0,"ttmEps":-2.021721,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786392000000},"marketStatusCode":2,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":27.35,"preHourTrading":{"tag":"盘前","latestPrice":27.02,"preClose":27.35,"latestTime":"09:29 EDT","volume":450,"amount":12289.710149999999,"timestamp":1786368599999,"change":-0.33,"changeRate":-0.012066,"amplitude":0.028154},"postHourTrading":{"tag":"盘后","latestPrice":27.48,"preClose":27.35,"latestTime":"19:34 EDT","volume":16021,"amount":438239.48,"timestamp":1786145641769,"change":0.13,"changeRate":0.004753,"amplitude":0.004753},"volumeRatio":0.829283,"impliedVol":0.9233,"impliedVolPercentile":0.5737},"requestUrl":"/m/hq/s/MLYS/wiki","defaultTab":"wiki","newsList":[{"id":"2656555653","title":"Mineralys Therapeutics to Report Q2 Results, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555653?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:04","pubTimestamp":1785845089,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics to report Q2 results, host conference callMineralys schedules second-quarter 2026 results release for Aug. 11, 2026, following the U.S. market close.Conference call set for Aug.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLbQlDd9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BKPKM429.USD","BK4112","BK4139","NDAQ","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4588","MLYS","IE00BN0W2W23.USD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654040921","title":"Mineralys Therapeutics Grants Inducement Equity Awards to New Hires Under 2025 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2654040921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654040921?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:01","pubTimestamp":1785182492,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics grants inducement equity awards to new hires under 2025 planMineralys Therapeutics granted inducement equity awards to two new non-executive employees under its 2025 Employment ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL98K9mt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","LU2095319765.USD","BCDF","BK4588","IE00BGHQF748.EUR","SG9999014013.SGD","MLYS","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4585","NDAQ","IE00B64PRP62.GBP","BK4112","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654919040","title":"Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654919040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654919040?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:01","pubTimestamp":1785182460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA22PBRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653771201","title":"Mineralys Chief Commercial Officer Eric Warren Disposes of $199,900 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2653771201","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653771201?lang=en_us&edition=fundamental","pubTime":"2026-07-24 06:40","pubTimestamp":1784846402,"startTime":"0","endTime":"0","summary":"Mineralys Chief Commercial Officer Eric Warren disposes of $199,900 in common sharesMineralys Therapeutics Chief Commercial Officer Eric Warren sold 7,438 shares on July 21, 2026 at USD 26.87 per shar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL75MDyx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Chief Commercial Officer Eric Warren Disposes of $199,900 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653601242","title":"Mineralys CMO David Malcom Rodman Disposes of 416 Common Shares Worth $11,036.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2653601242","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653601242?lang=en_us&edition=fundamental","pubTime":"2026-07-21 09:01","pubTimestamp":1784595671,"startTime":"0","endTime":"0","summary":"Mineralys CMO David Malcom Rodman disposes of 416 common shares worth $11,036.48Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 416 common shares at USD 26.53 on July 17, 2026.He","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL6pdlJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mineralys CMO David Malcom Rodman Disposes of 416 Common Shares Worth $11,036.48","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651923504","title":"Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 559,234 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2651923504","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651923504?lang=en_us&edition=fundamental","pubTime":"2026-07-16 08:58","pubTimestamp":1784163528,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics CMO David Malcom Rodman disposes of USD 559,234 in common sharesMineralys Therapeutics Chief Medical Officer Rodman David Malcom cut his stake to 51,384 shares following option ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL7r6hZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 559,234 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650158343","title":"Mineralys CMO David Malcom Rodman Sells 2,171 Common Shares Worth $65,781.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2650158343","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650158343?lang=en_us&edition=fundamental","pubTime":"2026-07-11 07:16","pubTimestamp":1783725363,"startTime":"0","endTime":"0","summary":"Mineralys CMO David Malcom Rodman sells 2,171 common shares worth $65,781.30Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 2,171 shares at $16 on July 9, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL7cpwsJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CMO David Malcom Rodman Sells 2,171 Common Shares Worth $65,781.30","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649142616","title":"Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649142616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649142616?lang=en_us&edition=fundamental","pubTime":"2026-07-06 08:35","pubTimestamp":1783298122,"startTime":"0","endTime":"0","summary":"In late June 2026, Mineralys Therapeutics, Inc. was removed from several Russell indices, including the Russell 3000E and Russell Microcap, while also reporting new ENDO 2026 data on lorundrostat’s effects on heart failure risk biomarkers and announcing a roughly US$150,000,000 public offering.\nAlongside revised licensing terms that give Mineralys full global rights to lorundrostat and access to up to US$500,000,000 in loan financing, the company’s recent moves suggest a stronger financial...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/did-index-removal-endo-2026-data-and-a-150m-raise-just-shift","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/did-index-removal-endo-2026-data-and-a-150m-raise-just-shift","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MLYS","BK4183","BK4139","ENDO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648666549","title":"Have Insiders Sold Mineralys Therapeutics Shares Recently?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648666549","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648666549?lang=en_us&edition=fundamental","pubTime":"2026-07-03 19:40","pubTimestamp":1783078831,"startTime":"0","endTime":"0","summary":"Some Mineralys Therapeutics, Inc. ( NASDAQ:MLYS ) shareholders may be a little concerned to see that the President, Jon...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/have-insiders-sold-mineralys-therapeutics-shares-recently","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/have-insiders-sold-mineralys-therapeutics-shares-recently","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4007","BK4539","BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648752509","title":"Mineralys Therapeutics (MLYS) Left Key Russell Indexes, Is The Stock Still Below Fair Value?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648752509","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648752509?lang=en_us&edition=fundamental","pubTime":"2026-07-02 03:45","pubTimestamp":1782935141,"startTime":"0","endTime":"0","summary":"Index removal puts Mineralys Therapeutics in focus\nMineralys Therapeutics (MLYS) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap series. This type of change can shift trading flows and short term demand for the stock.\nSee our latest analysis for Mineralys Therapeutics.\nAt a share price of $26.98, Mineralys Therapeutics has seen short term share price pressure, with the 30 day share price return down 14.35%, even as the 1 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/mineralys-therapeutics-mlys-left-key-russell-indexes-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/mineralys-therapeutics-mlys-left-key-russell-indexes-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648560077","title":"Mineralys CCO Eric Warren Disposes of 104,124 Common Shares for $2.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648560077","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648560077?lang=en_us&edition=fundamental","pubTime":"2026-07-01 06:41","pubTimestamp":1782859314,"startTime":"0","endTime":"0","summary":"Mineralys CCO Eric Warren disposes of 104,124 common shares for $2.7 millionMineralys Therapeutics Chief Commercial Officer Eric Warren sold 104,124 common shares on June 26 at USD 25.9.Sale followed ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL706GW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mineralys CCO Eric Warren Disposes of 104,124 Common Shares for $2.7 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644773913","title":"Mineralys Therapeutics director Daphne Karydas sells 3,000 shares valued at $75,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2644773913","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644773913?lang=en_us&edition=fundamental","pubTime":"2026-06-18 09:18","pubTimestamp":1781745516,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics director Daphne Karydas sold 3,000 common shares at USD 25 on June 17, 2026.She exercised stock options for 3,000 shares at USD 12.02 the same day.She held 6,200 common shares after the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL6jXlW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Therapeutics director Daphne Karydas sells 3,000 shares valued at $75,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643143221","title":"Mineralys posts ENDO 2026 lorundrostat biomarker presentation on uncontrolled hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2643143221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643143221?lang=en_us&edition=fundamental","pubTime":"2026-06-15 11:37","pubTimestamp":1781494623,"startTime":"0","endTime":"0","summary":"Mineralys published ENDO 2026 presentation materials on lorundrostat biomarker effects in uncontrolled hypertension, including treatment-resistant hypertension.Pooled analysis across Launch-HTN Phase 3 and Advance-HTN Phase 2b included 1,004 participants; 733 received lorundrostat, 271 received placebo.Week 12 pharmacodynamic data showed RAAS target engagement, including placebo-adjusted renin increases of 59.6% to 76.5%.Angiotensinogen fell 16.4% to 19.9% versus placebo; 106 biomarkers decreased, 85 increased at FDR < 0.05.Lorundrostat reduced 6 of 11 candidate causal incident heart failure risk biomarkers, including NT-proBNP; analysis linked changes to fibrosis and matrix remodeling pathways.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLC0pPy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643758247","title":"Mineralys Therapeutics presents late-breaking data on lorundrostat","url":"https://stock-news.laohu8.com/highlight/detail?id=2643758247","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643758247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:50","pubTimestamp":1781470205,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (MLYS) presented new data on the effect of lorundrostat on heart failure risk biomarkers. This post hoc analysis of circulat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","MLYS","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643224171","title":"Mineralys says lorundrostat reduces heart failure risk biomarkers in post hoc analysis of hypertension trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2643224171","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643224171?lang=en_us&edition=fundamental","pubTime":"2026-06-14 22:00","pubTimestamp":1781445619,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics presented late-breaking ENDO 2026 data from a post hoc proteomic analysis of lorundrostat in uncontrolled hypertension.The analysis showed reductions in several biomarkers linked to future heart-failure risk, supporting a potential disease-modifying signal beyond blood-pressure control.Findings also pointed to coordinated shifts consistent with less fibrosis, reinforcing the rationale to study lorundrostat in heart failure.Lorundrostat is under FDA review, with a PDUFA target date of December 22, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nNDL2BGvJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","LU0314104364.USD","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","BK4139","SG9999014013.SGD","MLYS","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643215343","title":"Mineralys CMO David Malcom Rodman disposes of common shares worth $203,512.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2643215343","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643215343?lang=en_us&edition=fundamental","pubTime":"2026-06-13 06:05","pubTimestamp":1781301928,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 8,519 common shares on June 10-12.Sales priced at USD 25 on June 10, then about USD 23.93 on June 12.He acquired 8,519 shares via option exercises at USD 16, then USD 1.08.Directly held stake ended unchanged at 63,443 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDLbfGJyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CMO David Malcom Rodman disposes of common shares worth $203,512.74","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431624","title":"Mineralys Therapeutics to join Goldman Sachs Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431624?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:14","pubTimestamp":1780949697,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8-10, 2026.Management is scheduled for a fireside chat on Tuesday, June 9, 2026 at 2:40 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL2lcYFl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360997.AUD","LU0942090050.USD","LU1894683348.USD","LU0096364046.USD","LU0868494708.USD","IE00B19Z3B42.SGD","LU0048573561.USD","BK4139","LU2471134523.USD","LU1668664300.SGD","LU2750360641.GBP","LU2237443382.USD","IE00BFXG1179.USD","IE0034235188.USD","BK4533","LU1868836914.USD","BK4127","LU1894683264.USD","LU2237443978.SGD","LU2237443895.HKD","GSX","LU1868836757.USD","BK4550","LU1804176565.USD","LU2237438978.USD","LU2237443622.USD","BK4516","LU0345770308.USD","LU1791807156.HKD","BK4588","LU2471134952.CNY","LU1868837300.USD","MLYS","LU0061475181.USD","LU1868837136.USD","LU2471134879.HKD","LU0868494617.USD","IE00B19Z3581.USD","BK4585","IE0004091025.USD","LU2237443465.HKD","IE00BSNM7G36.USD","LU0106831901.USD","LU0251131958.USD","BK4552","LU0251142724.SGD","LU1868836591.USD","IE0002270589.USD","LU0742534661.SGD","LU2265009873.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431190","title":"Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431190","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431190?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:05","pubTimestamp":1780949100,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., June  08, 2026  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3308453/0/en/Mineralys-Therapeutics-to-Participate-in-the-Goldman-Sachs-47th-Annual-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004086264.USD","IE00B19Z3B42.SGD","XBI","BK4539","LU2471134523.USD","BK4127","IE00B19Z3581.USD","LU0048573561.USD","LU2237443549.SGD","LU2471134796.USD","LU0942090050.USD","LU2471134952.CNY","GSX","LU1868837136.USD","BK4581","BK4516","LU1804176565.USD","LU2237443622.USD","LU2750360997.AUD","BK4007","LU1894683348.USD","IE0034235188.USD","IE0002270589.USD","LU0251142724.SGD","LU0345770993.USD","LENZ","LU0061475181.USD","BK4550","LU1868836914.USD","BK4552","LU0096364046.USD","LU0128526141.USD","LU0868494708.USD","LU1868836757.USD","LU1894683264.USD","MLYS","LU2237443978.SGD","BK4585","LU1791807156.HKD","LU2265009873.SGD","LABU","LU0742534661.SGD","BK4533","LU2471134879.HKD","LU2750360641.GBP","LU1868837300.USD","XLV","HCSG","LU2237438978.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640502841","title":"Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640502841","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640502841?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:00","pubTimestamp":1780578045,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-mineralys-therapeutics-inc-mlys-and-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-mineralys-therapeutics-inc-mlys-and-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0058720904.USD","AVBP","LU0029874061.USD","BK4585","VEEV","LU0266013472.USD","LU0289739699.SGD","LU0128526141.USD","LU0170899867.USD","BK4528","BK4534","LU1989764664.SGD","BK4613","BK4588","LU1989764748.USD","BK4581","BK4167","XBI","BK4504","BK4137","HCSG","MLYS","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640834811","title":"Mineralys Therapeutics falls -12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640834811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640834811?lang=en_us&edition=fundamental","pubTime":"2026-06-03 23:57","pubTimestamp":1780502226,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (MLYS) is down -12.7%, or -$3.67 to $25.18. Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-falls-12-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-falls-12-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","MLYS","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com;www.ir.mineralystx.com","stockEarnings":[{"period":"1week","weight":0.0717},{"period":"1month","weight":-0.1003},{"period":"3month","weight":-0.0741},{"period":"6month","weight":-0.0813},{"period":"1year","weight":1.1251},{"period":"ytd","weight":-0.2463}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014493},{"month":2,"riseRate":0.333333,"avgChangeRate":0.081442},{"month":3,"riseRate":0.25,"avgChangeRate":0.095856},{"month":4,"riseRate":0,"avgChangeRate":-0.078413},{"month":5,"riseRate":1,"avgChangeRate":0.100473},{"month":6,"riseRate":0.25,"avgChangeRate":-0.046559},{"month":7,"riseRate":0.5,"avgChangeRate":-0.030144},{"month":8,"riseRate":0.75,"avgChangeRate":0.019005},{"month":9,"riseRate":0.333333,"avgChangeRate":0.388697},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.001589},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0429},{"month":12,"riseRate":0.333333,"avgChangeRate":0.032291}],"exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction